Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April July May June August September October November December
Previous Archive
07 July 2023 | Story André Damons | Photo Supplied
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), with his certificate after winning the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

A research paper by a Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS) has won the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

The abstract, by Dr Osayande Evbuomwan, was about evaluating the efficacy of a new nuclear medicine radiopharmaceutical in the identification of active disease in patients with rheumatoid arthritis. It was selected for this award by a special committee at the recently concluded SNMMI 2023 Annual Meeting, which took place between 24 and 27 June in Chicago, USA.

Dr Evbuomwan received the award at the Annual Meeting on 26 June.

“It is a good feeling, and I am proud of the UFS Department of Nuclear Medicine for pulling this off. It is another example that hard work pays,” he says.

Comparing this radiopharmaceutical to ultrasound

Dr Evbuomwan says the research that generated the award-winning abstract was aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. The study concluded that this particular radiopharmaceutical (Tc – 99m glucosamine) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints), and is capable of offering prognostic information in patients with rheumatoid arthritis.

This is the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says. He is currently working on comparisons of this radiopharmaceutical to ultrasound and clinical evaluation in the identification of active disease in patients with rheumatoid arthritis. He says there is also ongoing collaboration with the Rheumatology Division of the Internal Medicine Department, which has played a huge role in making this project fruitful.

“This award is an opportunity to put the department and university on the map, with world stage recognition. We believe that as the Nuclear Medicine Department continues to grow in human resources and equipment, the research output will also increase.”

Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS, says the whole department is very proud of Dr Evbuomwan’s accomplishments. “What makes his award even more remarkable is that he outperformed candidates from much larger, highly funded institutions,” he says.

This department announced last year the successful treatment outcome of a patient with metastatic castrate-resistant prostate cancer (MCRPC) – an advanced stage of prostate cancer – by using Lutetium 177 PSMA (Lu-177 PSMA) therapy. This was initially a case of advanced stage prostate cancer, which had failed first-line chemotherapy, leaving little or no other treatment options.

News Archive

Professor awarded by Cardiff University for exceptional teaching and research record
2015-10-20

Prof Pieter Duvenage
Cardiff University is one of the best research universities in the United Kingdom (UK) and the world. In 2014, Cardiff was ranked number 2 and 5 among UK universities in the Research Excellence Framework for impact and quality, respectively.

Annually, Cardiff selects and recruits the most outstanding teachers and researchers from across the globe. This year, this institution bestowed on Professor Pieter Duvenage the title of Honorary Professorship in Political Philosophy for his contribution and commitment to philosophical research in South Africa and internationally. Prof Duvenage is Head of the Department of Philosophy at the University of the Free State (UFS).

Prof Duvenage has authored and co-authored four books, publishing almost 40 accredited articles in journals and books. As a distinguished scholar, he displays immense dedication to the investigation of the political implications of intellectual traditions.

Since 1997, Prof Duvenage has been lecturing philosophy as an associate professor, full professor, or visiting professor at various South African and Australian universities. He was appointed as Head of the Department of Philosophy in 2011, where he continues to explore his interests in Phenomenology, Critical Theory, and South African Intellectual History.

His rich academic history had earned him the prestigious five-year Honorary Professorship at Cardiff’s Department of Politics.  In 2014, the same university invited Prof Duvenage to be a Professorial Fellow of the Collingwood and British Idealism Centre for an indefinite period.

Professor David Boucher, Director of the Collingwood and British Idealism Centre, has played a crucial role in initiating both processes. According to Prof Duvenage, “Professor Boucher is a respected British academic and a Distinguished Visiting Professor at the University of Johannesburg.”

When Boucher announced the good news, Prof Duvenage was very surprised. “The appointment came as a total surprise. I never studied there [at Cardiff University], therefore it was purely through academic networks.”

Considering Cardiff’s reputation and Prof Duvenage’s exceptional skill sets and values, his relationship with the world-leading university in research is bound to blossom.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept